Advanced diagnostics Leverage Singulex Clarity's ultra-sensitive single molecule counting to position as a superior tool for early disease detection and monitoring, targeting hospitals, reference labs, and specialty clinics seeking highest assay sensitivity.

Regulatory readiness Highlight progress with FDA 510(k) submission and CE marking to reassure buyers about compliance and faster time-to-market for clinical assays, while offering collaboration on additional infectious and inflammatory disease panels.

Allied partnerships Pursue co-development and companion diagnostic opportunities with pharma and diagnostic players, leveraging existing collaborations with QIAGEN and Grifols to access broader distribution, validation, and reimbursement pathways.

Clinical expansion Target expansion into point-of-care and in vitro platform applications to address urgent needs for rapid, sensitive biomarkers in emergent care settings, driving portable system adoption in clinics and urgent care centers.

Market credibility Emphasize enterprise focus, commercial availability in Europe, and scalable manufacturing for mid-sized to large lab networks to appeal to multisite hospital systems seeking high-throughput, reliable immunodiagnostics workflows.